Published in Synapse on July 01, 2003
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem (2005) 3.32
Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates. Biol Psychiatry (2014) 1.40
PET/CT in diagnosis of movement disorders. Ann N Y Acad Sci (2011) 1.05
Neuroimaging in Parkinson's disease. Neurotherapeutics (2011) 0.95
Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol (2007) 0.90
In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol (2009) 0.89
Whole body [11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates. Eur J Nucl Med Mol Imaging (2007) 0.87
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging (2010) 0.85
Neurofunctional imaging of β-cell dynamics. Diabetes Obes Metab (2012) 0.82
In vivo beta-cell imaging with VMAT 2 ligands--current state-of-the-art and future perspective. Curr Pharm Des (2010) 0.81
Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence. Neuropsychopharmacology (2015) 0.77
A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination. ChemistryOpen (2015) 0.77
Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence. Eur J Neurosci (2016) 0.76
The role of dopamine and dopaminergic pathways in dystonia: insights from neuroimaging. Tremor Other Hyperkinet Mov (N Y) (2015) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A (2006) 3.30
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
The value of positron emission tomography in the clinical evaluation of dementia. J Am Geriatr Soc (2003) 2.05
The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J Biol Chem (2004) 1.97
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria. J Biol Chem (2003) 1.83
Current concepts in the diagnosis and management of Parkinson's disease. CMAJ (2003) 1.83
Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord (2008) 1.70
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain (2003) 1.70
An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Mov Disord (2011) 1.68
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain (2007) 1.66
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry (2010) 1.57
Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord (2012) 1.54
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology (2013) 1.50
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J Biol Chem (2007) 1.46
Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry (2010) 1.45
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain (2009) 1.44
Clustering of Parkinson disease: shared cause or coincidence? Arch Neurol (2004) 1.42
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain (2009) 1.40
Severe vascular disturbance in a case of familial brain calcinosis. Acta Neuropathol (2005) 1.38
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res (2002) 1.36
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem (2003) 1.28
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. Mov Disord (2003) 1.28
Toward [18F]-labeled aryltrifluoroborate radiotracers: in vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice. J Am Chem Soc (2008) 1.28
The placebo effect in Parkinson's disease. Trends Neurosci (2002) 1.24
Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet (2007) 1.24
Arylfluoroborates and alkylfluorosilicates as potential PET imaging agents: high-yielding aqueous biomolecular 18F-labeling. J Am Chem Soc (2005) 1.23
Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol (2005) 1.23
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain (2011) 1.20
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet (2002) 1.19
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol (2011) 1.19
The placebo effect in neurological disorders. Lancet Neurol (2002) 1.18
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci (2008) 1.12
Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2013) 1.12
Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med (2006) 1.10
Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol (2008) 1.10
Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl) (2008) 1.09
Functional imaging in Parkinson disease. Neurology (2008) 1.08
A mild form of adult-onset opsoclonus-myoclonus syndrome associated with antiglutamate receptor antibodies. JAMA Neurol (2013) 1.07
Cyclotron production of (99m)Tc: experimental measurement of the (100)Mo(p,x)(99)Mo, (99m)Tc and (99g)Tc excitation functions from 8 to 18 MeV. Nucl Med Biol (2011) 1.07
Manganese-52 positron emission tomography tracer characterization and initial results in phantoms and in vivo. Med Phys (2013) 1.07
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord (2004) 1.06
Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry (2004) 1.06
Substituent effects on aryltrifluoroborate solvolysis in water: implications for Suzuki-Miyaura coupling and the design of stable (18)F-labeled aryltrifluoroborates for use in PET imaging. J Org Chem (2008) 1.06
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord (2005) 1.05
Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord (2006) 1.03
Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. Eur J Hum Genet (2007) 1.03
PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry (2002) 1.03
Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord (2013) 1.02
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord (2005) 1.01
Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord (2010) 1.01
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord (2008) 1.00
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res (2008) 0.99